Literature DB >> 7672450

Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor.

B M Dickstein1, K Wosikowski, S E Bates.   

Abstract

Human breast cancer cells selected for multidrug resistance frequently overexpress ligands and receptors in the epidermal growth factor (EGF) receptor family. To determine whether this overexpression contributes to the drug resistant phenotype, EGF receptor transfected ZR75B human breast cancer cells were examined. Two EGF receptor overexpressing clones were evaluated: clone 11 with > 1 x 10(6) sites, and clone 13 with 310,000 receptor sites/cell. These were compared with clone 2-neo, which was transfected with the neomycin gene only and contained 43,000 receptor sites/cell. The EGF receptor overexpressing clones and the neo transfected control clone displayed comparable growth rates. Cytotoxicity analyses were performed with doxorubicin, vinblastine, cisplatin and 5-fluorouracil to determine the sensitivity of the clones to antineoplastic drugs. The EGF receptor overexpressing clones were found to be 1.5-5.6 times more resistant to the four drugs tested. This increase in the IC50 conferred a selective advantage when grown in the presence of 2, 3 and 6 ng/ml doxorubicin. Clone 13 cells overtook a mixed population which began with clone 2-neo comprising 95% of the cells. Clone 2-neo remained the dominant clone in the absence of drug. Finally, after long-term selection of the clones with 6 ng/ml doxorubicin, clone 2-neo became fourfold more resistant than the unselected clone 2-neo, a level which was comparable to that found in the EGF receptor overexpressing clones 11 and 13. No additional increase in resistance was observed for these clones, suggesting that clone 2-neo had developed additional resistance mechanisms.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7672450     DOI: 10.1016/0303-7207(95)03535-f

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  8 in total

1.  Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer.

Authors:  Carter Van Waes; Clint T Allen; Deborah Citrin; David Gius; A Dimetrios Colevas; Nancy A Harold; Susan Rudy; Liesl Nottingham; Christine Muir; Zhong Chen; Anurag K Singh; Janet Dancey; John C Morris
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-30       Impact factor: 7.038

Review 2.  Angiogenesis inhibitors in lung cancer.

Authors:  Edward S Kim; Roy S Herbst
Journal:  Curr Oncol Rep       Date:  2002-07       Impact factor: 5.075

Review 3.  Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy.

Authors:  E Raymond; S Faivre; J P Armand
Journal:  Drugs       Date:  2000       Impact factor: 9.546

Review 4.  Activated epidermal growth factor receptor in ovarian cancer.

Authors:  Laurie G Hudson; Reema Zeineldin; Melina Silberberg; M Sharon Stack
Journal:  Cancer Treat Res       Date:  2009

5.  Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer.

Authors:  D Nathan Kim; Taek-Keun Nam; Kevin S Choe; Hak Choy
Journal:  Cancer Res Treat       Date:  2012-06-30       Impact factor: 4.679

6.  ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas.

Authors:  A Orlandi; M Di Salvatore; C Bagalà; M Basso; A Strippoli; F Plastino; M A Calegari; A Cassano; A Astone; C Barone
Journal:  J Cancer       Date:  2015-01-01       Impact factor: 4.207

7.  Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells.

Authors:  C M Tsai; K T Chang; L Li; R P Perng; L Y Yang
Journal:  Jpn J Cancer Res       Date:  2000-02

Review 8.  Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization.

Authors:  Julia M W Gee; Robert I Nicholson
Journal:  Breast Cancer Res       Date:  2003-02-20       Impact factor: 6.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.